Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.
Location: United States
Employees: 11-50
Total raised: $118.9M
Founded date: 2013
Investors 9
Funding Rounds 3
| Date | Series | Amount | Investors |
| 16.10.2025 | - | $78M | Founders F... |
| 22.12.2020 | Series B | $35.4M | - |
| 01.10.2017 | Series A | $5.5M | - |
Mentions in press and media 21
| Date | Title | Description |
| 18.10.2025 | Peptilogics Secures $78M to Advance Breakthrough PJI Therapy Zaloganan | Peptilogics, a clinical-stage biotechnology firm, closed an oversubscribed $78 million Series B2 funding round. This capital propels zaloganan (PLG0206), its lead candidate, toward a pivotal Phase 2/3 clinical trial. Zaloganan targets prost... |
| 16.10.2025 | Peptilogics: $78 Million Raised For Advancing Zaloganan Toward Pivotal Trial For Prosthetic Joint Infections | Peptilogics, a clinical-stage biotechnology company pioneering surgical therapeutics for medical device infections, has closed an oversubscribed $78 million Series B2 financing round. The funding round was led by Presight Capital, Thiel Bio... |
| 16.10.2025 | Peptilogics Raises $78M in Series B2 Funding | Peptilogics, a Pittsburgh, PA-based clinical-stage biotechnology company developing surgical therapeutics to effectively treat and prevent serious medical device infections, closed a $78m Series B2 financing round. Presight Capital, Thiel B... |
| 12.01.2022 | Biotech startup Peptilogics just got FDA clearance to test the efficacy of its signature product | A Pittsburgh biotech startup has high hopes of making the city a center of AI-driven drug development for novel peptide therapeutics. South Side-based biotech startup Peptilogics announced this week that it had received FDA clearance to beg... |
| 13.04.2021 | Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy | |
| 17.03.2021 | Peptilogics Strengthens Leadership Team with Three Strategic Appointments | |
| 02.02.2021 | This Week in Jobs Pittsburgh: Prime Time Poet | Hi! You’re reading the Pittsburgh edition of This Week in Jobs (TWIJ), a weekly newsletter written by our team at Technical.ly in partnership with InnovatePGH and the Pittsburgh Innovation District. Each week we put together for you a slate... |
| 22.12.2020 | Peptilogics Receives $35.4M Series B Round | PITTSBURGH, PA, Peptilogics announced today the closing of a $35.4 million Series B financing. >> Click here for more funding data on Peptilogics >> To export Peptilogics funding data to PDF and Excel, click here The fina... |
| 22.12.2020 | Peptilogics Closes $35.4 Million Series B Financing | Peptilogics’ computational design platform accelerates the discovery and development of peptide therapeutics Peptilogics announced the closing of a $35.4 million Series B financing. The financing was led by Presight Capital, with participat... |
| 21.12.2020 | Peptilogics Closes $35.4 Million Series B Financing | Peptilogics announced today the closing of a $35.4 million Series B financing. The financing was led by Presight Capital, with participation from a new investor syndicate including Founders Fund as well as from existing investor Peter Thiel... |
Show more